Effects of simvastatin on blood lipids, vitamin E, coenzyme Q10 levels and left ventricular function in humans

European Journal of Clinical Investigation

Volumn 35, Issue 4, 2005, Pages 251-258

  Colquhoun, David M ^a   Jackson, R ^a   Walters, M ^c   Hicks, B J ^a   Goldsmith, J ^a   Young, P ^b   Strakosch, C ^a   Kostner, K M ^c  

^a WESLEY HOSPITAL   (Australia)

^b Wesley Research Institute   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Coenzyme Q10; Simvastatin; Ventricular function; Vitamin E

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER; SIMVASTATIN; TRIACYLGLYCEROL; UBIDECARENONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL MOTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VITAMIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS; CHOLESTEROL, LDL; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; SIMVASTATIN; UBIQUINONE; VENTRICULAR FUNCTION, LEFT; VITAMIN E;

EID: 17444396749     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01486.x     Document Type: Article

References (40)

1. Russell DW. Cholesterol biosynthesis and metabolism. Cardiovascular Drugs Ther 1992;6:103-10.
2. Folkers K, Langsjoen P, Willis R, Richardson P, Xia L-J, Ye C-Q, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4.
3. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S et al. Evidence of plasma CoQ 10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9.
4. Watts GF, Castelluccio C, Rice-Evans C, Taub NA, Baurn H, Quinn PJ. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7.
5. Laaksonen R, Ojala J-P, Tikkanen MJ, Hirnberg J-J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-7.
6. Sun IL, Sun EE, Crane FL, Morre DJ. Evidence for coenzyme Q function in transplasma membrane electron transport. Biochem Biophys Res Commun 1990;172:979-84.
7. Bashore TM, Magorien DJ, Letterio J, Schaffer P, Unverferth DV. Histological and biomedical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 1987;9:734-42.
8. 10. Proc Natl Acad Sci USA 1985;82:901-4.
9. Beyer RE, Nordenbrand K, Ernster L. The function of coenzyme Q in free radical production and as an antioxidant: a review. Chemica Scripta 1987;27:145-53.
10. Kontush A, Reich A, Baum K, Spranger T, Finckh B, Kohlschütter A et al. Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. Atherosclerosis 1997;129:119-26.
11. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc Natl Acad Sci USA 1991;88:1646-50.
12. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995;91:2488-96.
13. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992;41:766-72.
14. Hoffman R, Brook G, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and in vivo studies. Atherosclerosis 1992;93:105-13.
15. Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and á-tocopherol during lovastatin treatment. FEBS Lett 1997;410:254-8.
16. Okamoto T, Fukui K, Nakamoto M, Kishi T. High-performance liquid chromatography of CoQ-related compounds and its application to biological materials. J Chromatogr 1985;342:35-46.
17. 10 in one drop of human blood for biomedical research. Biochem Biophys Res Commun 1993;191:950-4.
18. Andersson S. Determination of CoQ by non-aqueous reversed-phase liquid chromatography. J Chromatogr 1992;606:272-6.
19. 10 and lipids in patients during total parental nutrition. J Nutr Sci Vitaminol 1986;32:1-12.
20. 10 from the liver to other tissues after intravenous administration to guinea pigs. Biochim Biophys Acta 1983;759:286-91.
21. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.
22. 10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tiss React 1990;XII:155-62.
23. Willis RA, Folkers K, Tucker JL, Ye CQ, Xia LJ, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990;87:8928-30.
24. Walker JF. Simvastatin: the clinical profile. Am J Med 1989;87 (Suppl. 4A):44S-46S.
25. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in press for a large mortality study. Eur Heart J 1994;15:255-69.
26. Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitiadis DS, Papageorgiou AA, Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolemic patients. Curr Med Res Opin 2003;19:22-7.
27. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart Disease. J Card Fail 1997;3:249-54.
28. Dariush M, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004;93:1124-9).
29. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003;108:839-43.
30. Nishimura RA, Abel MD, Hade LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of doppler echcardiography. Part II. Clinical studies. Mayo Clin Proc 1989;64:181-204.
31. Kishi T, Okamoto T, Takahashi T, Goshima K, Yamagami T. Cardiostimulatory action of coenzyme Q homologues on cultured myocardial cells and their biochemical mechanisms. Clin Invest 1993;71 (8 Suppl.):S71-5.
32. 10 content in different parts of the normal human heart. Clin Physiol 1988;8:391-8.
33. Rengo F, Abete P, Landino P, Leosco D, Covelluzzi F, Vitale D et al. Role of metabolic therapy in cardiovascular disease. Clin Invest 1993;71 (8 Suppl.):S124-8.
34. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52.
35. 10 and cardiac function. Nutr Metab Cardiovasc Dis 1993;3:193-6.
36. Tribble DL, van der Berg JJM, Motchnik PA, Ames BN, Lewis DM, Chait A et al. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and α-tocopherol content. Proc Natl Acad Sci USA 1994;91:1183-7.
37. Åberg F, Appelkvist E-L, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys 1992;295:230-4.
38. Frei B, Gaziano JM. Content of antioxidants, pre-formed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and - independent oxidation. J Lipid Res;34:2135-45.
39. Kontush A, Hübner C, Finckh B, Kohlschütter A, Beisiegel U. Low density lipoprotein oxidizability by copper correlates to its initial ubiquinol-10 and polyunsaturated fatty acid content. FEBS Lett 1994;341:69-73.
40. Palomäki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment, effect on LDL oxidation ex vivo. J Lipid Res 1998;39:1430-7.